Regeneron Pharmaceuticals | REGN - Vertriebs- Und Verwaltungskosten

Aktienkurs
751.57
Täglich Wechseln
-14.45 -1.89%
Monatlich
0.28%
Jährlich
24.71%
Q2 Prognose
735.49




Vertriebs- Und Verwaltungskosten Veränderung Datum
AbbVie USD 3.89B 325M 2025-12
Agenus USD 10.56M 13.04M 2025-12
Agios Pharmaceuticals USD 42.97M 1.7M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amgen USD 1.94B 237M 2025-12
Astellas Pharma JPY 221.78B 14.94B 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Biogen USD 545.2M 38.6M 2025-09
BioMarin Pharmaceutical USD 322.21M 98.79M 2025-12
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
J&J USD 6.03B 719M 2026-03
Kyowa Hakko Kirin JPY 43.89B 5.17B 2025-12
Merck USD 2.85B 215M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
Novartis USD 3.44B 132M 2025-12
Pfizer USD 4.08B 894M 2025-12
Puma Biotechnology USD 16.82M 8.15M 2024-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Teva Pharmaceutical Industries USD 1.12B 147M 2025-12
Ultragenyx Pharmaceutical USD 89M 2.38M 2025-12
United Therapeutics USD 190.6M 38.6M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12